文献园地
更多
TheranosticsDevelopment of a nanoparticle-based immunotherapy targeting CD137 for nasopharyngeal carcinoma treatment
International ImmunopharmacologySiglec-E deletion alters AT macrophages phenotypes, induces an inflammatory response, and adipogenesis during diet-induced obesity
Journal of Orthopaedic ResearchDepth-Wise Changes in Tibial and Femoral Human Knee Joint Cartilage at Different Severities of Osteoarthritis
品牌库
更多tranScrip Ltd
Established in October 2008, TranScrip Partners was specifically created to meet the needs of pharmaceutical companies forced to reduce head counts and consequent access to in-house drug development expertise. TranScrip is structured to fill this gap in the market and can provide pharmaceutical and life science companies with the expertise they require in a wide range of sub-disciplines and therapeutic areas, on both a short and long term basis, drawn from its extensive pool of Senior Partners and Partners.
Abbott B.V.
We are a global, broad-based health care company devoted to discovering new medicines, new technologies and new ways to manage health. Our products span the continuum of care, from nutritional products and laboratory diagnostics through medical devices and pharmaceutical therapies. Our comprehensive line of products encircles life itself - addressing important health needs from infancy to the golden years.
Formatech, Inc. Company dissolved
At Formatech, we help make new drugs happen… at the speed of science! Formatech, founded in 1993, provides contract services that deliver unique solutions to our clients' product development and manufacturing challenges. Our service offerings include: preformulation and formulation development of all common dosage forms, lyophilization development, cell culture/fermentation process development, purification/downstream process development and aseptic fill and finish of liquid and lyophilized dosage units. We have had excellent results developing biotherapeutic products. Our accomplishments include developing many Ab formulations at concentrations in excess of 200 mg/mL and an orally bioavailable peptide formulation. Our aseptic manufacturing facility produces liquid and lyophilized dosage units for clinical supplies or small-scale commercial products. Manufacturing support services include compounding/formulation, diafiltration/concentration (UF/DF), release testing, and ICH conforming stability programs. Our team is accomplished at completing new projects successfully even when confronted with very aggressive timelines. Our regulatory history includes FDA inspections and three inspections by the MHRA (letters and certificate of GMP compliance received).
GUS Schweiz AG
We optimize your business processes GUS ERP GmbH, GUS Nordic ApS and GUS Schweiz AG provide GUS-OS Suite, a web-based ERP business solution that includes all industry functionalities and fulfills regulatory requirements. The companies are members of the GSG GENII Software Group (www.gsg-genii.com), which offers leading, industry-specific software solutions and services, explicitly for medium-sized companies and public administrations. With its industry knowledge and personal customer relationships, the group of companies is a trustworthy partner and expert advisor to its customers. It accompanies its customers through digitization and ensures that they are equipped for the future in a volatile environment. GENII, headquartered in Munich, Germany, has generated sales of approximately 340 million euros with around 2,400 employees. GENII is backed by Bregal Unternehmerkapital and Elvaston.
GUS ERP GmbH
As a long-standing partner of the process industry, the GUS Group combines business competence with industry expertise and offers with GUS-OS ERP one of the most comprehensive software offerings for companies in the pharmaceutical, biotechnology, cosmetics, food and beverage, chemical and logistics industries. The GUS Group provides comprehensive consulting services, carries out projects and sets up IT infrastructures. Our own development team ensures continuous software innovations and the alignment of the solution with the norms and standards in our target industries. Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here .
Dr. August Wolff GmbH & Co. KG
Dr. August Wolff GmbH & Co. KG Arzneimittel is a family owned research oriented company still located in Bielefeld, Germany. Dr. August Wolff GmbH & Co. KG is selling medicinal products, medical devices and cosmetic products like Linola and Vagisan in several European countries. Since its inception in 1905 Dr. August Wolff has maintained strong focus in collaborations with universities to foster research and development in their search for novel products.
生知快讯
最新资讯
更多
47% 对 7%：衰老细胞清除第一次在随机对照里赢了一局
导语在脂肪肝的病程里，决定预后的不是脂肪有多少，而是瘢痕有多深。纤维化分期是代谢功能障碍相关脂肪性肝病（MASLD）患者发生肝相关并发症与死亡最强的预测因子，而目前已获批的 MASH 药物主要作用在代谢驱动上，对已经形成的纤维化作用有限。2026 年 10 月 1 日，《自然·代谢》发表了一项由阿姆斯特丹大学医学中
两项一模一样的 III 期，一项成一项败
导语甲状腺眼病（thyroid eye disease，TED）常被误当成"眼睛的问题"。实际上，病变发生在眼眶：自身抗体与炎症驱动眼眶成纤维细胞增殖、脂肪与眼外肌肿胀，最终纤维化。眼球突出、复视、眼睑退缩、眼痛，严重时压迫视神经导致视力丧失。这个病在美国每 10 万人中约 155 例，最常见于甲亢患者——约一半甲亢患者
一针覆盖整个流行季：国产 RSV 单抗把保护期拉到 9 个月
导语RSV 是婴幼儿下呼吸道感染最主要的病毒病原之一。世界卫生组织估计，它每年在全球导致约 3,300 万例 5 岁以下儿童肺部感染、360 万人次住院、10 余万人死亡。而在中国，这个领域长期没有一款本土的预防性抗体。2026 年 9 月 2 日，珠海泰诺麦博的芮特韦拜单抗注射液（商品名新多妥）获国家药监局批准上市；10 月 20 日